Beximco Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Beximco Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 15.6% bzw. 12.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 18.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.8% betragen.

Wichtige Informationen

15.6%

Wachstumsrate der Gewinne

18.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	12.8%
Zukünftige Eigenkapitalrendite	14.8%
Analystenabdeckung	Low
Zuletzt aktualisiert	09 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DSE:BXPHARMA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (BDT Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	64,949	8,688	7,352	9,216	3
6/30/2026	57,171	7,464	6,868	8,545	3
6/30/2025	50,423	6,244	5,719	7,151	3
6/30/2024	44,506	5,251	4,894	6,146	3
3/31/2024	43,085	5,330	5,962	8,373	N/A
12/31/2023	41,652	4,916	5,696	8,176	N/A
9/30/2023	40,639	4,720	5,486	8,109	N/A
6/30/2023	39,267	4,614	3,442	6,085	N/A
3/31/2023	37,974	4,477	2,650	5,562	N/A
12/31/2022	37,379	4,629	1,323	3,922	N/A
9/30/2022	35,987	5,105	1,161	3,910	N/A
6/30/2022	34,669	5,123	2,275	5,214	N/A
3/31/2022	33,660	5,738	3,143	5,950	N/A
12/31/2021	32,062	6,097	4,153	7,502	N/A
9/30/2021	31,037	5,519	3,983	6,796	N/A
6/30/2021	29,494	5,128	3,465	6,023	N/A
3/31/2021	28,269	4,578	3,667	5,592	N/A
12/31/2020	27,517	4,017	2,198	4,025	N/A
9/30/2020	26,235	3,724	2,354	4,895	N/A
6/30/2020	25,612	3,515	3,267	5,542	N/A
3/31/2020	25,056	3,405	-187	4,319	N/A
12/31/2019	24,202	3,251	834	5,814	N/A
9/30/2019	23,735	3,143	-114	4,397	N/A
6/30/2019	22,817	3,033	-1,585	2,960	N/A
3/31/2019	21,724	2,852	-300	2,893	N/A
12/31/2018	20,188	2,708	-2,393	1,397	N/A
9/30/2018	18,823	2,647	-3,106	1,611	N/A
6/30/2018	17,717	2,537	-3,239	1,819	N/A
3/31/2018	16,924	2,513	-2,547	2,416	N/A
12/31/2017	16,517	2,431	N/A	2,873	N/A
9/30/2017	16,022	2,356	N/A	2,643	N/A
6/30/2017	15,509	2,227	N/A	2,634	N/A
3/31/2017	14,687	2,224	N/A	2,042	N/A
12/31/2016	14,271	2,133	N/A	1,883	N/A
9/30/2016	13,736	2,060	N/A	1,932	N/A
6/30/2016	13,356	1,965	N/A	2,113	N/A
12/31/2015	12,966	1,954	N/A	1,835	N/A
9/30/2015	12,573	1,804	N/A	2,095	N/A
6/30/2015	12,134	1,813	N/A	1,937	N/A
3/31/2015	11,628	1,605	N/A	2,510	N/A
12/31/2014	11,207	1,528	N/A	2,216	N/A
9/30/2014	11,139	1,476	N/A	2,459	N/A
6/30/2014	10,847	1,471	N/A	2,146	N/A
3/31/2014	10,804	1,452	N/A	2,196	N/A
12/31/2013	10,491	1,405	N/A	2,130	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BXPHARMADas prognostizierte Gewinnwachstum (15.6% pro Jahr) liegt über der Sparquote (3.7%).

Ertrag vs. Markt: BXPHARMADie Erträge des Unternehmens (15.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt BD (17% pro Jahr).

Hohe Wachstumserträge: BXPHARMADie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: BXPHARMADie Einnahmen des Unternehmens (12.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BD (8% pro Jahr).

Hohe Wachstumseinnahmen: BXPHARMADie Einnahmen des Unternehmens (12.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BXPHARMADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.8 %).

Beximco Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 9.3% to ৳168

Price target increased to ৳182

Consensus EPS estimates increase by 18%

Analysts increase EPS estimates to ৳10.32

Price target raised to ৳114

Price target raised to ৳113

Recent updates

Price target increased by 9.3% to ৳168

Third quarter 2024 earnings released: EPS: ৳3.06 (vs ৳2.13 in 3Q 2023)

Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024

Second quarter 2024 earnings released: EPS: ৳3.21 (vs ৳2.77 in 2Q 2023)

Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Upcoming dividend of ৳3.50 per share at 2.4% yield

Full year 2023 earnings released: EPS: ৳10.34 (vs ৳11.48 in FY 2022)

Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Beximco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 19, 2023

Third quarter 2023 earnings released: EPS: ৳2.13 (vs ৳2.47 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ৳2.77 (vs ৳3.84 in 2Q 2022)

Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS misses analyst expectations

Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended 30 June 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to ৳182

Less than half of directors are independent

Now 20% undervalued after recent price drop

Consensus EPS estimates increase by 18%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Beximco Pharmaceuticals Limited Launches First Generic Version of Pfizer's COVID-19 Treatment Paxlovid

Upcoming dividend of ৳3.50 per share

Full year 2021 earnings released: EPS ৳11.49 (vs ৳7.88 in FY 2020)

Third quarter 2021 earnings released: EPS ৳3.28 (vs ৳2.02 in 3Q 2020)

Investor sentiment improved over the past week

Beximco Pharmaceuticals Limited Updates on the Supply of Covid-19 Vaccine

Second quarter 2021 earnings released: EPS ৳2.54 (vs ৳1.93 in 2Q 2020)

Analysts increase EPS estimates to ৳10.32

Price target raised to ৳114

Beximco Pharmaceuticals Limited Announces Board Changes

Beximco Pharmaceuticals Limited Provides Update on the Supply of COVID-19 Vaccine

Beximco Pharmaceuticals Limited Confirms Quamrun Naher Ahmed and Reem H. Shamsuddoha as Non-Executive Directors

Investor sentiment improved over the past week

New 90-day high: ৳170

New 90-day high: ৳159

Beximco Pharmaceuticals Limited Announces Directors Appointments

New 90-day high: ৳148

Price target raised to ৳113

New 90-day high: ৳148

Price target raised to ৳116

New 90-day high: ৳145

First quarter 2021 earnings released: EPS ৳2.65

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ৳8.67

Beximco Pharmaceuticals Limited Enters into A Memorandum of Understanding for the Supply and Distribution of 30 Million Doses of the Oxford University/AstraZeneca SARS-CoV-2 Vaccine, AZD1222, in Bangladesh

New 90-day high: ৳127

Beximco Pharmaceuticals Limited Receives US Food and Drug Administration (Fda) Approval for Antiarryhtmic Drug Flecainide

Price target raised to ৳105

New 90-day high - ৳116

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken